Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Patience

<< Previous

Bullboard Posts

Next >>

Comment by allain250on Jul 20, 2018 10:59am

50 Views

Post# 28344298

RE:RE:RE:RE:RE:RE:Patience

"iCo Therapeutics has a good sense of doses which may be examined in upcoming later staged clinical studies," commented Dr. Kishor Wasan, co-inventor of the technology and Professor and Dean, College of Pharmacy and Nutrition, University of Saskatchewan, in Monday’s news release. iCo now plans to move forward with clinical trials to evaluate the efficacy of the drug candidate in sick patients.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading